Recent developments in patented DC-based immunotherapy for various malignancies

Recent Patents on Regenerative Medicine

Volumn 1, Issue 1, 2011, Pages 72-87

  Harada, Yui ^a,b   Yonemitsu, Yoshikazu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antigen; Dendritic cell (DC); Expansion; Immunotherapy; Malignancies; Maturation

Indexed keywords

EID: 84859774974     PISSN: 22102965     EISSN: 22102973     Source Type: Journal    
DOI: 10.2174/2210297311101010072     Document Type: Article

References (187)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11): e442.
2. Starnes CO. Coley's toxins in perspective. Nature 1992; 357(6373): 11-12.
3. Knuth A, Wolfel T, Klehmann E, Boon T, Meyer zum Buschenfelde KH. Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci USA 1989; 86(8): 2804-2808.
4. Laus, R., Ruegg, C.L., Wu, H. Immunostimulatory compositions. US005976546 (1999).
5. Laus, R., Ruegg, C.L., Wu, H. Immunostimulatory method. US006080409 (2001).
6. Laus, R., Shapero, M.H., Tsavaler, L. Prostate tumor polynucleotide compositions and methods of detection thereof. US006194152 (2001).
7. Laus, R., Ruegg, C.L., Wu, H. Immunostimulatory composition. US006210662 (2002).
8. Laus, R., Ruegg, C.L., Shapero, M.H., Yang, D. Composition and method for producing an immune response against tumor-related antigens. US007414108 (2008).
9. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137(5): 1142-1162.
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. J Exp Med 1974; 139(2): 380-397.
11. Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 1975; 141(4): 804-820.
12. Iwasaki H, Akashi K. Myeloid lineage commitment from the hematopoietic stem cell. Immunity 2007; 26(6): 726-740.
13. Onai N, Obata-Onai A, Schmid MA, Ohteki T, Jarrossay D, Manz MG. Identification of clonogenic common Flt3+M-CSFR+plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow. Nat Immunol 2007; 8(11): 1207-1016.
14. Waskow C, Liu K, Darrasse-Jeze G, Guermonprez P, Ginhoux F, Merad M, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol 2008; 9(6): 676-683.
15. Conti L, Gessani S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: Recent advances. Immunobiology 2008; 213(9/10): 859-870.
16. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4): 783-801.
17. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5(4): 296-306.
18. Faure F, Mantegazza A, Sadaka C, Sedlik C, Jotereau F, Amigorena S. Long-lasting cross-presentation of tumor antigen in human DC. Eur J Immunol 2009; 39(2): 380-390.
19. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393(6684): 480-483.
20. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6(11): 1123-1132.
21. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13(2): 139-145.
22. Rieser C, Bock G, Klocker H, Bartsch G, Thurnher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: Synergistic activation of interleukin 12 production. J Exp Med 1997; 186(9): 1603-1608.
23. Kalinski P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 2001; 97(11): 3466-3469.
24. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, et al. Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 2009; 15(6): 633-640.
25. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based therapeutic vaccination against cancer. Curr Opin Immunol 2005; 17(2): 163-169.
26. Esche C, Lokshin A, Shurin GV, Gastman BR, Rabinowich H, Watkins SC, et al. Tumor's other immune targets: Dendritic cells. J Leukoc Biol 1999; 66(2): 336-344.
27. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-529.
28. Esche C, Shurin GV, Kirkwood JM, Wang GQ, Rabinowich H, Pirtskhalaishvili G, et al. Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanomainduced apoptosis. Clin Cancer Res 2001; 7(3 Suppl): 974s-979s.
29. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2(4): 293-299.
30. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59: 56-58.
31. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005; 23: 1407-1413.
32. Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarriere N, et al. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients. Clin Cancer Res 2006; 12: 7380-7388.
33. Scandella E, Men Y, Gillessen S, Forster R, Groettrup M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 2002; 100: 1354-1361.
34. Dallal RM, Lotze MT. The dendritic cell and human cancer vaccines. Curr Opin Immunol 2000; 12(5): 583-588.
35. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
36. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines (review). Int J Oncol 2001; 18(3): 475-478.
37. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15(17): 5323-5337.
38. Sugiyama, H. WT1 modified peptide. US20090325886 (2009).
39. Franz-Georg, H., Stefan, M. Peptide variants of the tumor marker MUC1 and their application. US20090054622 (2009).
40. Toni, W., Claudia, L., Hans-Georg, R., Stefan, S. MHC moleculebinding tumor-associated peptides. US20100021441 (2010).
41. Shih-Jen, L., Hsin-Wei, C., Pele, C.S.C. Immunopeptides of HPV E6 and E7 proteins. US20090117123 (2009).
42. Bob, S.C., Richard, C.M., Szofia, B. Chimeric T-cell receptors and T-cells targeting egfrviii on tumors. US20100105136 (2010).
43. Christoph, Z., Otto, S., Hubert, P., Heimo, B., Ursula, W. HER- 2/NEU multi-peptide vaccine. US20090269364 (2009).
44. Esteban, C., Scott, E.S. Mage-A3/HPV 16 peptide vaccines for head and neck cancer. US20100183646 (2010).
45. Noguchi, Y., Chen, Y.T., Old, L.J. Compositions containing a P53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof. US6355256 (2002).
46. Valmori, D., Cerottini, J.C., Romero, P. NY-ESO-1 peptide derivatives, and uses thereof. US6605711 (2003).
47. Liu, L., Bot, A., Gong, J., Diamond, D. PSMA peptide analogues. US7511118 (2009).
48. Ferrone, S., Tsao, C.Y., Wang, X., Luo, W., Cheung, N.K.V. GD2 peptide mimics. US6939948 (2005).
49. Schlom, J., Barzaga, E., Zaremba, S. Agonist and antagonist peptides of carcinoembryonic antigen (CEA). US20100209386 (2010).
50. Tuthill, C., Rios, I. Treatment of melanoma with alpha thymosin peptides. US20100197595 (2010).
51. Guo, Z., Lu, Y., Bellgrau, D., Franzusoff, A. Ras mutation and compositions and methods related thereto. US20100215678 (2010).
52. Hwu, P., LaPointe, R., Rosenberg, S.A., Parkhurst, M. Peptides of melanoma antigen and their use in diagnostic, prophylactic and therapeutic methods. US7419957 (2008).
53. Molldrem, J., Barrett, A.J. Anti-cancer vaccines. WO2005019435 (2005).
54. Scheinberg, D.A., Pinilla-Ibarz, J. BCR-ABL vaccines and methods of use thereof. WO2007047763 (2007).
55. Wang, R.F., Rosenberg, S.A. Human cancer antigen of tyrosinaserelated protein 1 and genes encoding same. EP1411124 (2008).
56. Ciesielski, M.J., Fenstermaker, R.A. Survivin peptides as cancer vaccines. US20090041732 (2009).
57. Stenman, U.H., Koivunen, E., Leinonen, J., Narvanen, A. Peptide ligands for prostate specific antigen. US20080312141 (2008).
58. Langlade-Demoyen, P., Garcia, P.F., Adotevi, O., Cardinaud, S., Neuveut, C. Polynucleotides encoding MHC class I-restricted htert epitopes, analogues thereof or polyepitopes. US20100172878 (2010).
59. Kinch, M.S., Zantek, N.D., Hein, P.W. EPHA2 as a therapeutic target for cancer. US7776327 (2010).
60. Wollan, J.B., Jones, L.A. Promiscuous PAP CD4 T cell epitopes. WO2008022030 (2008).
61. Straten, P.T., Andersen, M.H. Therapeutic cancer vaccine. WO2004089980 (2004).
62. Andersen, T.T., Bennett, J.A., Jacobson, H., Shields, G.C., Kirschner, K.N. Alpha-fetoprotein peptides. US20090203624 (2009).
63. Kuzushima, K. Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific ctl and use of the same. WO2005068632 (2005).
64. Guilloux, Y., Jotereau, F., Boon-Falleur, T., Lucas, S., Brichard, V. Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof. WO1996040039 (1996).
65. Berzofsky, J.A., Van Den Broeke, L.T., Mackall, C., Helman L.J. Immunogenic peptides and methods of use for treating and preventing cancer. WO2007055902 (2007).
66. Hreczuk-Hirst, D.H., Jain, S., Laing, P., Gregoriadis, G., Papaioannou, I. Polysialic acid derivatives. US20100221808 (2010).
67. Houghton, A.N., Naftzger, C., Vijayasaradhi, S. Method and compositions for stimulation of an immune response to TRP2 using a xenogeneic TRP2 antigen. US20100068263 (2010).
68. Ferrone, S., Wang, X., Chi-Feng, H.J., Tsao, C.Y., Luo, W. GD3 peptide mimics. US6998237 (2006).
69. Livingston, P.O., Ragupathi, G., Danishefsky, S.J. Polyvalent conjugate vaccine for cancer. US7479266 (2009).
70. Jaffee, E., Wu, T.C., Hung, C.F., Hruban, R. Mesothelin vaccines and model systems. US20090165152 (2009).
71. Van, S.J., Lethe, B., Chaux, P., Boon-Falleur, T., van der Bruggen, P. MAGE-A1 peptides presented by HLA class II molecules. US7157091 (2007).
72. Aziz, N., Hedley, M.L., Urban, R.G., Tomlinson, A.J., Cole, G. CYP1B1 nucleic acids and methods of use. US7241742 (2007).
73. Cabezon, S.T.E.V., Ellis, J.H., Gerard, C.M.G., Hamblin, P.A., Palmantier, R.M., Vinals, Y. de B.C. Immunogenic compositions. WO2003104272 (2003).
74. Wong, C.H., Wu, C.Y., Yu, A., Yu, J. GLOBO H and related anticancer vaccines with novel glycolipid adjuvants. US20100136042 (2010).
75. Weinschenk, T., Lemmel, C., Rammensee, H.G., Stevanovic, S. MHC molecule-binding tumor-associated peptides. US20100021441 (2010).
76. Itoh, K., Harada, M. SART3-derived peptide useful in cancer vaccine therapy for HLA-A3 supertype allele-positive prostate cancer patient. WO2008007711 (2008).
77. Pastorek, J., Barathova, M. MN/CA9 splice variants. US20100056611 (2010).
78. Itoh, K., Noguchi, M., Harada, M. LCK-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for HLAA3 supertype allele. WO2009022652 (2009).
79. Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006; 211(6-8): 599-608.
80. + T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virus. J Immunol 2009; 183(7): 4211-4219.
81. Mackensen A, Herbst B, Chen JL, Kohler G, Noppen C, Herr W, et al. Phase I study in melanoma patients of a vaccine with peptidepulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer 2000; 86(3): 385-392.
82. Schuler G, Steinman RM. Dendritic cells as adjuvants for immunemediated resistance to tumors. J Exp Med 1997; 186(8): 1183-1187.
83. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 2008; 57(10): 1559-1568.
84. Herr W, Wolfel T, Heike M, Meyer zum Buschenfelde KH, Knuth A. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol Immunother 1994; 39: 93-99.
85. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, et al. Phenotypic analysis of antigenspeciWc T lymphocytes. Science 1996; 274: 94-96.
86. Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, et al. Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 1997; 71: 932-936.
87. Dunbar PR, Ogg GS, Chen J, Rust N, van der Bruggen P, Cerundolo V. Direct isolation, phenotyping and cloning of lowfrequency antigen-speciWc cytotoxic T lymphocytes from peripheral blood. Curr Biol 1998; 8: 413-416.
88. Fabre JW. The allogeneic response and tumor immunity. Nat Med 2001; 7: 649.
89. Kleindienst P, Brocker T. Endogenous dendritic cells are required for amplification of T cell responses induced by dendritic cell vaccines in vivo. J Immunol 2003; 170: 2817.
90. Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, et al. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 2005; 54(7): 663-670.
91. Hus I, Roliński J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19(9): 1621-1627.
92. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191(5): 795-804.
93. Apostolopoulos V, Pietersz GA, McKenzie IF. MUC1 and breast cancer. Curr Opin Mol Ther 1999; 1(1): 98-103.
94. Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, Cloughesy TF, et al. Treatment of intracranial gliomas with bone marrowderived dendritic cells pulsed with tumor antigens. J Neurosurg 1999; 90(6): 1115-1124.
95. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190(11): 1669-1678.
96. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96(9): 3102-3108.
97. Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, et al. Cancer cells engineered to secrete granulocytemacrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46 Suppl: S67-S72.
98. Tjoa BA, Murphy GP. Development of dendritic-cell based prostate cancer vaccine. Immunol Lett 2000; 74(1): 87-93.
99. Treon SP, Raje N, Anderson KC. Immunotherapeutic strategies for the treatment of plasma cell malignancies. Semin Oncol 2000; 27(5): 598-613.
100. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi H, et al. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. Vaccine 2001; 19(17/19): 2549-2556.
101. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166(6): 4254-4259.
102. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: Recent developments. Oncology 2001; 60(1): 1-7.
103. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004; 10(5): 475-480.
104. Lipscomb MF, Masten BJ. Dendritic cells: Immune regulators in health and disease. Physiol Rev 2002; 82(1): 97-130.
105. Cerio R, Griffiths CE, Cooper KD, Nickoloff BJ, Headington JT. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989; 121(4): 421-431.
106. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha. J Exp Med 1996; 184(2): 695-706.
107. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180(1): 83-93.
108. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179(4): 1109-1118.
109. + progenitors. J Leukoc Biol 1999; 66(5): 781-791.
110. Ito T, Inaba M, Inaba K, Toki J, Sogo S, Iguchi T, et al. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol 1999; 163(3): 1409-1419.
111. + dendritic cells. Proc Natl Acad Sci USA 1996; 93(6): 2588-2592.
112. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 1997; 185(6): 1101-111.
113. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 5(8): 919-923.
114. Kohrgruber N, Halanek N, Groger M, Winter D, Rappersberger K, Schmitt-Egenolf M, et al. Survival, maturation, and function of CD11c- and CD11c+ peripheral blood dendritic cells are differentially regulated by cytokines. J Immunol 1999; 163(6): 3250-3259.
115. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferonproducing cells in human blood. Science 1999; 284(5421): 1835-1837.
116. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1(12): 1297-1302.
117. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2(1): 52-58.
118. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4(3): 328-332.
119. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10(9): 909-915.
120. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F. Kinetics of dendritic cell activation: Impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000; 1(4): 311-316.
121. Hugues S, Fetler L, Bonifaz L, Helft J, Amblard F, Amigorena S. Distinct T cell dynamics in lymph nodes during the induction of tolerance and immunity. Nat Immunol 2004; 5(12): 1235-1242.
122. Huang, F.P., Chen, Y.X., Man, K. Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10. US20090010948 (2009).
123. Kirkin, A., Djandjougazian, K., Zeuthen, J. Method for generating dendritic cells employing decreased temperature. US20090196856 (2009).
124. Braughler, J.M., Kumar, P., Storkus, W.J., Okada, H. Engineered dendritic cells and uses for the treatment of cancer. US20090123441 (2009).
125. Kalinski, P. Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use. US20090004157 (2009).
126. Markwell MA, Svennerholm L, Paulson JC. Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci USA 1981; 78(9): 5406-5410.
127. Nagai Y. Paramyxovirus replication and pathogenesis. Reverse genetics transforms understanding. Rev Med Virol 1999; 9(2): 83-99.
128. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, et al. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: Implications for immunotherapy. J Exp Med 1997; 186(5): 645-653.
129. Yonemitsu Y, Kitson C, Ferrari S, Farley R, Griesenbach U, Judd D, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18(9): 970-973.
130. Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata-Takeshita H, et al. Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene. J Immunol 2006; 177(6): 3564-3576.
131. Thielemans, K.M.M., Bonehill, A. Enhancing the T-cells stimulatory capacity of human antigen presenting cells and their use in vaccination. US20100215674 (2010).
132. Ten, B.J.A., Van, H.S.M., Zwaginga, J.J. Maturation of dendritic cells. US20090297541 (2009).
133. Spencer, D., Hanks, B., Slawin, K. Induced activation in dendritic cell. US007404950 (2008).
134. Salgaller, M., Boynton, A. Method to increase class I presentation of exogenous antigens by human dendritic cells. US20080171023 (2008).
135. Hasumi, K. Dendritic cell tumor injection (DCTI) therapy. US20060216269 (2006).
136. Schendel, D.J., Bigalke, I., Zobywalski, A. Compositions for the preparation of mature dendritic cells. WO2007110240 (2007).
137. Kai, C., Kato, A. Process for preparation of cytokines using Sendai virus expression system. US006514728 (2003).
138. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001; 409(6823): 1055-1060.
139. Siren J, Sareneva T, Pirhonen J, Strengell M, Veckman V, Julkunen I, et al. Cytokine and contact-dependent activation of natural killer cells by influenza A or Sendai virus-infected macrophages. J Gen Virol 2004; 85(Pt 8): 2357-2364.
140. Bell E. NK cells need a license to kill. Nat Rev Immunol 2005; 5: 674.
141. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol Rev 2006; 214: 155-160.
142. Castillo EF, Stonier SW, Frasca L, Schluns KS. Dendritic cells support the in vivo development and maintenance of NK cells via IL-15 trans-presentation. J Immunol 2009; 183(8): 4948-4956.
143. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206(1): 25-34.
144. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Microbiol 2005; 3(1): 59-69.
145. Mandelboim O, Porgador A. NKp46. Int J Biochem Cell Biol 2001; 33(12): 1147-1150.
146. Draghi M, Pashine A, Sanjanwala B, Gendzekhadze K, Cantoni C, Cosman D, et al. NKp46 and NKG2D recognition of infected dendritic cells is necessary for NK cell activation in the human response to influenza infection. J Immunol 2007; 178(5): 2688-2698.
147. Ahlert, T. Activation of antigen-specific T cells by virus/antigentreated dendritic cells. US20090060946 (2009).
148. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894-3903.
149. Laus, R., Gold, M.H., Peshwa, M., Pickering, G., Kylstra, J. Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers. US20040161413 (2004).
150. Tatsuta K, Tanaka S, Tajiri T, Shibata S, Komaru A, Ueda Y, et al. Complete elimination of established neuroblastoma by synergistic action of gamma-irradiation and DCs treated with rSeV expressing interferon-beta gene. Gene Ther 2009; 16(2): 240-251.
151. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009; 27: 669-692.
152. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Science 2009; 325(5940): 612-616.
153. Sieweke, M. Method for expanding monocytes. US20100003272 (2010).
154. Kelly LM, Englmeier U, Lafon I, Sieweke MH, Graf T. MafB is an inducer of monocytic differentiation. EMBO J 2000; 19(9): 1987-1997.
155. + peripheral blood progenitor cell and monocyte derived dendritic cells: A comparative analysis. Br J Haematol 1997; 99(3): 490-499.
156. + T cells. J Immunol 1999; 163(7): 3597-3604.
157. Syme R, Bajwa R, Robertson L, Stewart D, Glück S. Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells 2005; 23(1): 74-81.
158. Harada Y, Ueda Y, Kinoh H, Komaru A, Fuji-Ogawa T, Furuya A, et al. Cytokine-based log-scale expansion of functional murine dendritic cells. PLoS One 2009; 4(8): e6674.
159. Bontkes HJ, De Gruijl TD, Schuurhuis GJ, Scheper RJ, Meijer CJ, Hooijberg E. Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J Leukoc Biol 2002; 72(2): 321-329.
160. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61(17): 6451-6458.
161. Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, et al. Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replicationdeficient vaccinia vector encoding the human tyrosinase gene: A phase I trial. Hum Gene Ther 2003; 14(14): 1347-1360.
162. Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: A phase I trial in metastatic melanoma. Clin Cancer Res 2004; 10(16): 5381-5390.
163. Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, et al. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006; 55(10): 1209-1218.
164. + hematopoietic progenitor cells. Blood 1990; 75(12): 2292-2298.
165. + cell-derived dendritic cells and monocytes with lymphocyte-tropic and monocyte-tropic HIV-1 strains. J Immunol 1997; 158(10): 5035-5042.
166. Rondelli D, Lemoli RM, Ratta M, Fogli M, Re F, Curti A, et al. Rapid induction of CD40 on a subset of granulocyte colonystimulating factor-mobilized CD34(+) blood cells identifies myeloid committed progenitors and permits selection of nonimmunogenic CD40(-) progenitor cells. Blood 1999; 94(7): 2293-2300.
167. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol 1995; 154(11): 5851-5861.
168. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: Stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91(4): 1101-1134.
169. + cells. Br J Haematol 1998; 101(4): 756-765.
170. + cells. Transfusion 2009; 49(10): 2109-2121.
171. Inoue, M., Hasegawa, A.M., Yonemitsu, Y., Harada, Y. Method for production of dendritic cell. WO2008143047 (2008).
172. Ueda, Y., Yonemitsu, Y., Harada, Y. Method for producing dendritic cells. WO2010055900 (2010).
173. Rodin S, Domogatskaya A, Strom S, Hansson EM, Chien KR, Inzunza J, et al. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat Biotechnol 2010; 28(6): 611-615.
174. Fairchild PJ, Brook FA, Gardner RL, Graca L, Strong V, Tone Y, et al. Directed differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol 2000; 10(23): 1515-1518.
175. Senju S, Hirata S, Matsuyoshi H, Masuda M, Uemura Y, Araki K, et al. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood 2003; 101(9): 3501-3508.
176. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: Application to antitumor vaccination. J Immunol 2004; 172(2): 776-786.
177. Fukuma D, Matsuyoshi H, Hirata S, Kurisaki A, Motomura Y, Yoshitake Y, et al. Cancer prevention with semi-allogeneic ES cellderived dendritic cells. Biochem Biophys Res Commun 2005; 335(1): 5-13.
178. Matsuyoshi H, Hirata S, Yoshitake Y, Motomura Y, Fukuma D, Kurisaki A, et al. Therapeutic effect of alpha-galactosylceramideloaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci 2005; 96(12): 889-896.
179. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16- F10. Cancer Res 2006; 66(4): 2414-2422.
180. Senju S, Suemori H, Zembutsu H, Uemura Y, Hirata S, Fukuma D, et al. Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells 2007; 25(11): 2720-2729.
181. Waldmann, H., Fairchild, P.J., Gardner, R., Brook, F. Method for producing dendritic cells. US7247480 (2007).
182. Slukvin, I.I., Thomson, J.A., Vodyanyk, M.A., Gumenyuk, M.E. Method of forming dendritic cells from embryonic stem cells. US20060275901 (2006).
183. Lynch, D.H., Brasel, K.A., McKenna, H.J., Borges, L.G., Maliszewski, C.R., Maraskovsky, E. Methods of preparing dendritic cells with FLT3-ligand and antigen. US7150992 (2006).
184. Edelson, R.L., Berger, C.L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells. US20070281354 (2007).
185. + progenitorderived dendritic cells from G-CSF-mobilized peripheral mononuclear cells does not require hematopoietic stem cell enrichment. J Leukoc Biol 2007; 81(4): 957-967.
186. Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, Takahashi K, et al. Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 2009; 27(5): 1021-1031.
187. Su Z, Frye C, Bae KM, Kelley V, Vieweg J. Differentiation of human embryonic stem cells into immunostimulatory dendritic cells under feeder-free culture conditions. Clin Cancer Res 2008; 14(19): 6207-6217.